$SUPV

Grupo Supervielle (NYSE:SUPV) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen has upgraded Grupo Supervielle (NYSE:SUPV) from a "sell" to a "hold" rating, aligning with the stock's consensus "Hold" rating and $13.33 average target price. This upgrade comes despite the company reporting a significant earnings miss and lower-than-expected revenue. The stock's current market cap is around $922 million, with a P/E of 87.7 and notable recent volatility.

Original reporting
MarketBeat · MarketBeat
Published Feb 15, 2026, 7:03 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Feb 15, 2026, 8:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Grupo Supervielle (NYSE:SUPV) Upgraded by Wall Street Zen to "Hold" Rating — source image
Decision brief

The 30-second read

$SUPVNeutralLow
01

Why it matters

The upgrade may stabilize investor sentiment temporarily, but fundamental concerns limit upside potential. The high valuation warrants caution.

02

Market read

The news is relevant primarily to investors holding or considering exposure to Latin American financial stocks, with limited broader market impact.

03

What to watch

Potential upcoming catalysts such as strategic initiatives, macroeconomic changes, or regulatory developments that could influence the stock's trajectory.

Timing: short-term

Background

Grupo Supervielle reported a significant earnings miss and lower-than-expected revenue, leading to a cautious outlook. The recent analyst upgrade to 'Hold' indicates a neutral stance amid mixed fundamentals.

Company-level read

Ticker impact

$SUPVNeutralMedium confidence
Context

The news pertains directly to Grupo Supervielle, a NYSE-listed financial institution, with a recent analyst upgrade from Wall Street Zen.

Expected impact

Potential sideways movement with slight upward bias in the short term; long-term trend uncertain without earnings recovery.

Evidence & confidence

The upgrade reflects analyst sentiment shift, but earnings miss and high valuation introduce uncertainty. Technical indicators are not provided, limiting precise short-term predictions.

$SUPVNeutralMedium confidence
Context

The sentiment score of 0.014104 indicates a neutral market perception of the stock, aligning with the analyst upgrade and earnings report.

Expected impact

Likely minimal immediate price change; longer-term movement depends on earnings trajectory.

Evidence & confidence

The low relevance score suggests limited immediate trading impact; technical and fundamental data are insufficient for precise forecasts.

Market effects

The financial sector may experience slight volatility due to earnings reports and analyst ratings; sector-wide sentiment remains cautious.

Limited regional impact; primarily affects investors in Latin America and US markets with exposure to Latin American financial stocks.

Minimal; the news is specific to a regional financial institution with limited global influence.

Counterpoint

The earnings miss could be a short-term anomaly; the analyst upgrade suggests potential for future recovery, making the stock attractive for contrarian investors.

Key entities

  • Grupo Supervielle

    A financial services company listed on NYSE, operating primarily in Latin America.

Related articles

$SUPVMed

Supervielle (SUPV) Swings Back To Profit As Layoffs Reshape The Bank

Grupo Supervielle (SUPV) reported a net income of AR$12.8 billion for Q2, reversing a prior loss, driven by a 17% workforce reduction and cost-cutting. Adjusted net income was AR$36.2 billion, with an adjusted ROAE of 12.4%. Lending metrics improved, with net interest income up 13.1% and NPL ratio at 5.5%. However, the bank posted a net loss of AR$5.4 billion for H1, with ROAA at 0.6% for Q2 and -0.1% for H1.

Med

Grupo Supervielle SA (SUPV) (Q2 2026) Earnings Call Highlights: Return to Profitability

Grupo Supervielle SA (SUPV) reported Q2 2026 earnings, highlighting a return to profitability. Loan demand declined, and net fee income is expected to fall 5%-8%. NIM guidance was lowered to 17%-19%, and ROE is projected at 2%-4% for 2026. Management expects cost savings to reflect in metrics from Q3, with loan growth guidance reduced to 10%-15%. IOL's net income decreased due to lower trading activity but saw growing assets under custody.

$SUPVMedAI 8/10

Grupo Supervielle Reports 2Q26 Results

Grupo Supervielle S.A. (NYSE: SUPV; BYMA: SUPV) reported 2Q26 results for the period ended June 30, 2026. It returned to profitability with attributable net income of AR$12.8bn and ROAE of 4.4%, or structural net income AR$41.9bn and structural ROAE 14.4% excluding extraordinary severance. NPL ratio fell to 5.5% and net cost of risk to 5.6%.

$SUPVMed

Grupo Supervielle S.A. (SUPV): Financial results for Q2 2026

Grupo Supervielle S.A. (SUPV) furnished an SEC Form 6-K — earnings release. Yes ☐ No ☒ ​ ​ ​ GRUPO SUPERVIELLE S.A. TABLE OF CONTENTS ​ ​ ​Item ​ ​ ​1. Grupo Supervielle S.A. – 2Q26 Earnings Report ​ ​ ​ ​ ​ Content Financial highlights & Key ratios ‌ 9 Review of consolidated results ‌ 13 Profitability & Comprehensive Income ‌ 13 Net financial income ‌ 1

$BBVAMed

Argentine country risk drops below 450 points, hitting 8

S&P upgraded Argentina’s sovereign credit rating from CCC+ to B- on Thursday, citing reduced economic vulnerability and improved external liquidity and debt-servicing capacity, including reserve accumulation and fiscal balance. Argentina’s country-risk index fell to 444 bps (below 450). Dollar bonds rose up to 3.3% and the S&P Merval gained 5.68% (7.3% in hard currency); ADRs climbed as much as 11.5%.

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.